The FDA has granted accelerated approval for Rezdiffra, marking it as the first drug specifically for treating non-alcoholic steatohepatitis (NASH), a serious form of fatty liver disease. This approval allows for earlier access to treatments for conditions with significant unmet medical needs, based on intermediate clinical endpoints that suggest potential clinical benefits.